Who
Leonard E. Post
Director
Company insider
Files Form 4 as: Director, CG Oncology; Director, uniQure; Director, Fulgent Genetics; Director, Praecis Pharmaceuticals.
In numbers
- Trades disclosed
- 110
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $2.8M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 7 Feb 2007
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $6001,000 at $0.60 | filing |
| 15 Oct 2026filed 19 Oct 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $31K500 at $61.65 | filing |
| 15 Oct 2026filed 19 Oct 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $31K500 at $62.48 | filing |
| 15 Oct 2026filed 19 Oct 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $6001,000 at $0.60 | filing |
| 15 Sep 2026filed 17 Sep 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $73K1,000 at $72.98 | filing |
| 15 Sep 2026filed 17 Sep 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $6001,000 at $0.60 | filing |
| 15 Sep 2026filed 17 Sep 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $73K1,000 at $72.98 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $6001,000 at $0.60 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $75K1,000 at $74.54 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $6001,000 at $0.60 | filing |
| 14 Aug 2026filed 18 Aug 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $75K1,000 at $74.54 | filing |
| 15 Jul 2026filed 17 Jul 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Code M | $6001,000 at $0.60 | filing |
| 15 Jul 2026filed 17 Jul 2026 | CGON CG OncologyBiotechnology | SEC FORM 4 Sold | $71K1,000 at $71.17 | filing |
| 15 Jul 2026filed 17 Jul 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
News
uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $53.25QURE · dailypolitical.com · 24 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)QURE · tickerreport.com · 13 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastQURE · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Leonard E. Post; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.